Medpace Holdings, Inc. reported significant financial growth in its latest quarterly results, with net revenue reaching $659.9 million for the three months ended September 30, 2025, a 23.7% increase from $533.3 million in the same period last year. For the nine months ended September 30, 2025, revenue totaled $1.82 billion, up 15.9% from $1.57 billion in the prior year. The company's net income also rose, amounting to $111.1 million for the third quarter, compared to $96.4 million in 2024, and $316.0 million for the nine-month period, up from $287.4 million.
The increase in revenue was primarily driven by growth in the Metabolic, Oncology, and Central Nervous System therapeutic areas. Total direct costs for the third quarter increased to $463.0 million, up from $364.3 million, largely due to higher reimbursed out-of-pocket expenses and personnel costs associated with increased service activities. Selling, general, and administrative expenses saw a slight decrease in the third quarter but increased for the nine-month period, reflecting the company's investment in operational growth.
Operationally, Medpace expanded its workforce to approximately 6,200 employees across 44 countries as of September 30, 2025. The company reported a backlog of $3.0 billion, a 2.5% increase from the previous year, indicating strong future revenue potential. The company also executed a substantial share repurchase program, buying back nearly 2.96 million shares for $912.9 million during the nine months ended September 30, 2025, with $821.7 million remaining under the repurchase authorization.
Looking ahead, Medpace anticipates continued growth driven by its disciplined operating model and strategic focus on full-service clinical development services. The company plans to invest in operational growth, including potential acquisitions and infrastructure improvements, while maintaining a strong liquidity position with $285.4 million in cash and cash equivalents as of the end of the reporting period. The management remains optimistic about the company's ability to navigate market conditions and capitalize on opportunities in the clinical research sector.
About Medpace Holdings, Inc.
Medpace Holdings, Inc. is a global clinical contract research organization (CRO) providing full-service Phase I-IV clinical development services to the biotech, pharmaceutical, and medical device industries. Focused on therapeutic areas like Oncology, CNS, and Cardiovascular, it supports drug development through trial management, regulatory guidance, data sciences, and laboratory services. Its business model emphasizes quality, efficiency, and deep therapeutic expertise to serve small and mid-sized biopharma companies worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.